Breast cancer incidence, case-fatality and breast cancer mortality in Danish women using hormone replacement therapy - A prospective observational study

International Journal of Epidemiology

Volumn 34, Issue 4, 2005, Pages 931-935

  Stahlberg, Claudia ^a   Lynge, Elsebeth ^a   Andersen, Zorana Jovanovic ^a   Keiding, Niels ^a   Ottesen, Bent ^a   Rank, Fritz ^a,b   Hundrup, Yrsa Andersen ^c   Obel, Erik B ^c   Pedersen, Anette Tønnes ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Breast neoplasm; Epidemiology; Estrogen; Hormone replacement therapy; Menopause; Mortality; Progestin; Prognosis

Indexed keywords

SEX HORMONE;

CANCER;

ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER INVASION; CANCER MORTALITY; CANCER REGISTRY; CANCER RISK; CANCER STAGING; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DENMARK; FATALITY; FEMALE; FOLLOW UP; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; NURSE; PATIENT INFORMATION; POPULATION RESEARCH; POSTAL MAIL; POSTMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; QUESTIONNAIRE; RISK ASSESSMENT; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

AGED; BREAST NEOPLASMS; DENMARK; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUESTIONNAIRES;

EID: 26444473209     PISSN: 03005771     EISSN: 14643685     Source Type: Journal    
DOI: 10.1093/ije/dyi103     Document Type: Article

References (28)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108,411 women without breast cancer. [i#Lancet#1i] 1997; [b#350#1b] 1047-59.
2. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. [i#Lancet#1i] 2003;[b#362#1b]:419-27.
3. Rossouw JE, Anderson GL, Prentice RL [i#et al.#1i] Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. [i#JAMA#1i] 2002;[b#288#1b]:321-33.
4. Jernstrom H, Bendahl PO, Lidfeldt J, Nerbrand C, Agardh CD, Samsioe G. A prospective study of different types of hormone replacement therapy use and the risk of subsequent breast cancer: The women's health in the Lund area (WHILA) study (Sweden). [i#Cancer Causes Control#1i] 2003;[b#14#1b] 673-80.
5. Magnusson C, Baron JA, Correia N, Bergstrom R, Adam HO, Persson I. Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy. [i#Int J Cancer#1i] 1999;[b#81#1b] 339-44.
6. Olsson HL, Ingvar C, Bladstrom A. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden. [i#Cancer#1i] 2003;[b#97#1b]:1387-92.
7. Stahlberg C, Pedersen AT, Lynge E [i#et al.#1i] Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. [i#Int J Cancer#1i] 2004;[b#109#1b]:721-27.
8. Tjonneland A, Christensen J, Thomsen BL [i#et al.#1i] Hormone replacement therapy in relation to breast carcinoma incidence ratios. A prospective Danish cohort study. [i#Cancer#1i] 2004;[b#100#1b]:2328-37.
9. Bilimoria MM, Winchester DJ, Sener SF, Motykie G, Sehgal UL, Winchester DP. Estrogen replacement therapy and breast cancer: Analysis of age of onset and tumor characteristics. [i#Ann Surg Oncol#1i] 1999;[b#6#1b] 200-07.
10. Esteve J, Seradour B, Jacquemier J, Remontet L. Does a better grade of tumour occurring in women under hormone replacement therapy compensate for their lower probability of detection by screening mammography? [i#J Med Screen#1i] 2002;[b#9#1b]:70-73.
11. Gertig DM, Erbas B, Fletcher A, Amos A, Kavanagh AM. Duration of hormone replacement therapy, breast tumour size and grade in a screening programme. [i#Breast Cancer Res Treat#1i] 2003;[b#80#1b]:267-73.
12. Harding C, Knox WF, Faragher EB, Baildam A, Bundred NJ. Hormone replacement therapy and tumour grade in breast cancer: Prospective study in screening unit. [i#BMJ#1i] 1996;[b#312#1b]:1646-47.
13. Holli K, Isola J, Cuzick J. Hormone replacement therapy and biological aggressiveness of breast cancer. [i#Lancet#1i] 1997;[b#350#1b]:1704-05.
14. Magnusson C, Holmberg L, Norden T, Lindgren A, Persson I. Prognostic characteristics in breast cancers after hormone replacement therapy. [i#Breast Cancer Res Treat#1i] 1996;[b#38#1b]:325-34.
15. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: Estrogen versus estrogen plus progestin. [i#J Natl Cancer Inst#1i] 2000;[b#92#1b]:328-32.
16. Sacchini V, Zurrida S, Andreoni G [i#et al.#1i] Pathologic and biological prognostic factors of breast cancers in short- and long-term hormone replacement therapy users. [i#Ann Surg Oncol#1i] 2002;[b#9#1b]:266-71.
17. Stahlberg C, Pedersen AT, Andersen ZJ [i#et al.#1i] Breast cancer with different prognostic characteristics developing in women using hormone replacement therapy. [i#Br J Cancer#1i] 2004;[b#91#1b]:644-50.
18. Nanda K, Bastian LA, Schulz K. Hormone replacement therapy and the risk of death from breast cancer: A systematic review. [i#Am J Obstet Gynecol#1i] 2002;[b#186#1b]:325-34.
19. Dano H, Andersen O, Ewertz M, Petersen JH, Lynge E. Socioeconomic status and breast cancer in Denmark. [i#Int J Epidemiol#1i] 2003;[b#32#1b]:218-24.
20. Rodstrom K, Bengtsson C, Lissner L, Bjorkelund C. Pre-existing risk factor profiles in users and non-users of hormone replacement therapy: prospective cohort study in Gothenburg, Sweden. [i#BMJ#1i] 1999;[b#319#1b] 890-93.
21. Kerlikowske K, Miglioretti DL, Ballard-Barbash R [i#et al.#1i] Prognostic characteristics of breast cancer among postmenopausal hormone users in a screened population. [i#J Clin Oncol#1i] 2003;[b#21#1b]:4314-21.
22. Chlebowski RT, Hendrix SL, Langer RD [i#et al.#1i] Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative Randomized Trial. [i#JAMA#1i] 2003;[b#289#1b]:3243-53.
23. Hulley S, Furberg C, Barrett-Connor E [i#et al.#1i] Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/ progestin Replacement Study follow-up (HERS II). [i#JAMA#1i] 2002;[b#288#1b] 58-66.
24. Hedblad B, Merlo J, Manjer J, Engstrom G, Berglund G, Janzon L. Incidence of cardiovascular disease, cancer and death in postmenopausal women affirming the use of hormone replacement therapy. [i#Scand J Public Health#1i] 2002;[b#30#1b]:12-19.
25. Holmberg L, Anderson H, HABITS steering and data monitoring committees. HABITS (hormonal replacement therapy after breast cancer - is it safe?), a randomized comparison: Trial stopped. [i#Lancet#1i] 2004;[b#363#1b] 453-55.
26. Jernstrom H, Frenander J, Ferno M, Olsson H. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. [i#Br J Cancer#1i] 1999;[b#80#1b]:1453-58.
27. Reeves GK, Patterson J, Vessey MP, Yeates D, Jones L. Hormonal and other factors in relation to survival among breast cancer patients. [i#Int J Cancer#1i] 2000;[b#89#1b]:293-99.
28. Schairer C, Gail M, Byrne C [i#et al.#1i] Estrogen replacement therapy and breast cancer survival in a large screening study. [i#J Natl Cancer Inst#1i] 1999;[b#91#1b]:264-70.